IP Verse

Boult Wade Tennant competitive analysis

Explore patent oppositions filed by Boult Wade Tennant against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 10, 2026

Patent Number	Title	Applicant	Opposition Date
EP4364724	High Concentration Vegf Receptor Fusion Protein Containing Formulations	REGENERON PHARMACEUTICALS	Aug 25, 2026
EP4034870	Systems And Methods For Chromatography Use And Regeneration	REGENERON PHARMACEUTICALS	Aug 18, 2026
EP4374919	Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	Jul 28, 2026
EP4619213	Method And Apparatus Relating To Injection Molding Contact Lens Mold Halves	COOPERVISION	Jul 10, 2026
EP3697494	Leadless Pacing Device For His Bundle And Bundle Branch Pacing	MEDTRONIC	Jun 3, 2026
EP4185318	Extended, High Dose Vegf Antagonist Regimens For Treatment Of Angiogenic Eye Disorders	BAYER HEALTHCARE	Jun 3, 2026
EP3407884	Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression Innpm1	MEMORIAL SLOAN KETTERING CANCER CENTER	Apr 8, 2026
EP4461308	Toxicity Management For Anti-Tumor Activity Of Cars	THE CHILDRENS HOSPITAL OF PHILADELPHIA	Jan 13, 2026
EP3689383	Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen	THE UNITED STATES OF AMERICA	Dec 31, 2025
EP3824905	Method And Compositions For Cellular Immunotherapy	FRED HUTCHINSON CANCER CENTER	Oct 8, 2025

Discover the latest PTAB cases involving Boult Wade Tennant, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Boult Wade Tennant with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 10, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
BOULT WADE TENNANT	62	-	-	-
DANA FARBER CANCER INSTITUTE	-	25	3	1
REGENERON PHARMACEUTICALS	55	142	9	32
SANOFI BIOTECHNOLOGY	-	59	-	-